
Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Vinpocetine is a semi-synthetic alkaloid derived from the periwinkle plant that enhances cerebral blood flow and cognitive function. It works by inhibiting phosphodiesterase-1 and blocking voltage-gated sodium channels, improving oxygen delivery to brain tissue.

Reported Benefits (Provisional)
Origin & History

Vinpocetine is a synthetic derivative of the alkaloid vincamine, which is extracted from the periwinkle plant, Vinca minor. It is produced through a chemical process that modifies vincamine to enhance its bioavailability and efficacy.
Research Narrative (Provisional)
Vinpocetine has been studied in various clinical trials, including randomized controlled trials (RCTs) and observational studies, showing potential benefits in cognitive enhancement and neuroprotection. However, more large-scale studies are needed to confirm these effects.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
- Synthetic compound, not naturally occurring in foods. - Primarily used in supplement form. - Typically available in 5 mg to 10 mg doses.
Reported Mechanism (Provisional)
Vinpocetine inhibits cyclic GMP-specific phosphodiesterase-1, increasing cGMP levels and promoting vasodilation in cerebral blood vessels. It blocks voltage-gated sodium channels and modulates calcium influx, reducing neuronal excitotoxicity. Additionally, it enhances glucose uptake and ATP synthesis in brain cells while inhibiting adenosine reuptake.
Clinical Narrative (Provisional)
Human studies show vinpocetine (10-40mg daily) improves cognitive performance in elderly adults with mild cognitive impairment, with effect sizes of 0.3-0.7 in memory tests. A systematic review of 19 trials found modest improvements in cerebral blood flow velocity measured by transcranial Doppler. However, most studies are small-scale (30-100 participants) and short-term (2-16 weeks). Evidence quality remains moderate due to methodological limitations in older trials.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.







